Sutro Biopharma has partnered with Celgene to design and develop antibody-drug conjugates (ADCs) and bispecific antibodies against two undisclosed Celgene targets. The California-based company has also agreed to manufacture an antibody from Celgene’s early-stage pipeline. The deal, which is Celgene’s third of the past year that is focused on next-generation antibody therapies, provides a validation of Sutro’s cell-free protein synthesis platform, which allows for the rapid and systematic exploration of protein drug variants and which may reduce the time it takes to get an ADC into the clinic by as much as 1 year.